Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
-- JCAR015 IND FDA clearance allows initiation of Juno's first pivotal trial -- -- Transformative partnership with Celgene -- -- Substantial R&D progress with key acquisition integrations on...
-
SEATTLE, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the second quarter of 2015 on Wednesday, August 12, 2015 after the close of...
-
SEATTLE, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...
-
-- Multi-center, pivotal Phase 2 trial to begin in the near term -- SEATTLE, July 30, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on...
-
SEATTLE, June 29, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...
-
SEATTLE, June 3, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it will webcast its presentation at the Goldman Sachs 36th Annual Global Healthcare Conference at...
-
-- Transaction Accelerates Capabilities to Create Novel Fully Human CAR T and TCR Constructs -- -- Initial Payment of Approximately $21 Million in Cash and 439,265 Shares of Juno Stock...
-
SEATTLE, June 1, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. announced today that clinical data from a chimeric antigen receptor (CAR) T cell product candidate, JCAR014, demonstrated encouraging...
-
SEATTLE, May 30, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) announced today that clinical data from its most advanced chimeric antigen receptor (CAR) T cell product candidate,...
-
SEATTLE, May 28, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...